{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T18:17:59Z","timestamp":1758046679376,"version":"3.44.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.pharma.2022.11.009","type":"journal-article","created":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T22:36:52Z","timestamp":1668638212000},"page":"466-474","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Implementing Alfred60AST in a clinical lab: Clinical impact on the management of septic patients and financial analysis"],"prefix":"10.1016","volume":"81","author":[{"given":"M.","family":"Potvin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Larranaga Lapique","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Hites","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Martiny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.pharma.2022.11.009_bib0190","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1007\/s00134-016-4577-z","article-title":"Sepsis: frontiers in diagnosis, resuscitation and antibiotic therapy","volume":"42","author":"Perner","year":"2016","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.pharma.2022.11.009_bib0195","doi-asserted-by":"crossref","first-page":"6976923","DOI":"10.1155\/2018\/6976923","article-title":"A prospective evaluation of two rapid phenotypical antimicrobial susceptibility technologies for the diagnostic stewardship of sepsis","volume":"2018","author":"Giordano","year":"2018","journal-title":"Biomed Res Int"},{"issue":"2","key":"10.1016\/j.pharma.2022.11.009_bib0200","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s00134-001-1143-z","article-title":"Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study","volume":"28","author":"Alberti","year":"2002","journal-title":"Intensive Care Med"},{"issue":"16","key":"10.1016\/j.pharma.2022.11.009_bib0205","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1056\/NEJMoa022139","article-title":"The epidemiology of sepsis in the United States from 1979 through 2000","volume":"348","author":"Martin","year":"2003","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.pharma.2022.11.009_bib0210","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1128\/JCM.01831-09","article-title":"Rapid identification of bacteria from positive blood culture bottles by use of matrix-assisted laser desorption-ionization time of flight mass spectrometry fingerprinting","volume":"48","author":"Christner","year":"2010","journal-title":"J Clin Microbiol"},{"issue":"Suppl 3","key":"10.1016\/j.pharma.2022.11.009_bib0215","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.1093\/cid\/ciu547","article-title":"Review of rapid diagnostic tests used by antimicrobial stewardship programs","volume":"59","author":"Bauer","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.pharma.2022.11.009_bib0220","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1097\/01.CCM.0000217961.75225.E9","article-title":"Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock","volume":"34","author":"Kumar","year":"2006","journal-title":"Crit Care Med"},{"issue":"3","key":"10.1016\/j.pharma.2022.11.009_bib0225","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s00134-017-4683-6","article-title":"Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016","volume":"43","author":"Rhodes","year":"2017","journal-title":"Intensive Care Med"},{"issue":"3","key":"10.1016\/j.pharma.2022.11.009_bib0230","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.21037\/jtd.2020.01.47","article-title":"An approach to antibiotic treatment in patients with sepsis","volume":"12","author":"Mart\u00ednez","year":"2020","journal-title":"J Thorac Dis"},{"issue":"11","key":"10.1016\/j.pharma.2022.11.009_bib0235","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1097\/CCM.0000000000000516","article-title":"Using the number needed to treat to assess appropriate antimicrobial therapy as a determinant of outcome in severe sepsis and septic shock","volume":"42","author":"Vazquez-Guillamet","year":"2014","journal-title":"Crit Care Med"},{"issue":"1","key":"10.1016\/j.pharma.2022.11.009_bib0240","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.emc.2016.08.003","article-title":"Appropriate antibiotic therapy","volume":"35","author":"Allison","year":"2017","journal-title":"Emerg Med Clin North Am"},{"issue":"4","key":"10.1016\/j.pharma.2022.11.009_bib0245","first-page":"298","article-title":"Current aspects in sepsis approach. Turning things around","volume":"31","author":"Candel","year":"2018","journal-title":"Rev Esp Quimioter"},{"issue":"7","key":"10.1016\/j.pharma.2022.11.009_bib0250","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1099\/jmm.0.000997","article-title":"Rapid antimicrobial susceptibility tests for sepsis; the road ahead","volume":"68","author":"Inglis","year":"2019","journal-title":"J Med Microbiol"},{"issue":"9","key":"10.1016\/j.pharma.2022.11.009_bib0255","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1007\/s10096-019-03595-y","article-title":"Evaluation of the Alfred AST\u00ae system for rapid antimicrobial susceptibility testing directly from positive blood cultures","volume":"38","author":"S\u00e1nchez-Carrillo","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"12","key":"10.1016\/j.pharma.2022.11.009_bib0260","doi-asserted-by":"crossref","first-page":"E568","DOI":"10.1111\/1469-0691.12282","article-title":"Impact of rapid microbial identification directly from positive blood cultures using matrix-assisted laser desorption\/ionization time-of-flight mass spectrometry on patient management","volume":"19","author":"Martiny","year":"2013","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"10.1016\/j.pharma.2022.11.009_bib0265","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1473-3099(15)70112-X","article-title":"Sepsis: a roadmap for future research","volume":"15","author":"Cohen","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.pharma.2022.11.009_bib0270","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/CM9.0000000000000101","article-title":"Rules of anti-infection therapy for sepsis and septic shock","volume":"132","author":"Zhou","year":"2019","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"10.1016\/j.pharma.2022.11.009_bib0275","doi-asserted-by":"crossref","first-page":"e1700750","DOI":"10.1002\/biot.201700750","article-title":"Identification and antibiotic-susceptibility profiling of infectious bacterial agents: a review of current and future trends","volume":"14","author":"Maugeri","year":"2019","journal-title":"Biotechnol J"},{"issue":"1","key":"10.1016\/j.pharma.2022.11.009_bib0280","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1093\/cid\/ciaa528","article-title":"Randomized Trial evaluating clinical impact of rapid identification and susceptibility testing for gram-negative bacteremia: RAPIDS-GN","volume":"73","author":"Banerjee","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.pharma.2022.11.009_bib0285","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10096-019-03690-0","article-title":"Performance and potential clinical impact of Alfred60AST(Alifax\u00ae) for direct antimicrobial susceptibility testing on positive blood culture bottles","volume":"39","author":"Van den Poel","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"1","key":"10.1016\/j.pharma.2022.11.009_bib0290","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s12866-019-1654-9","article-title":"Evaluation of a new Rapid Antimicrobial Susceptibility system for Gram-negative and Gram-positive bloodstream infections: speed and accuracy of Alfred 60AST","volume":"19","author":"Anton-Vazquez","year":"2019","journal-title":"BMC Microbiol"},{"issue":"1","key":"10.1016\/j.pharma.2022.11.009_bib0295","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1186\/s12879-019-4623-x","article-title":"Rapid antimicrobial susceptibility testing on positive blood cultures through an innovative light scattering technology: performances and turnaround time evaluation","volume":"19","author":"Boland","year":"2019","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.pharma.2022.11.009_bib0300","doi-asserted-by":"crossref","first-page":"106433","DOI":"10.1016\/j.mimet.2022.106433","article-title":"Antimicrobial susceptibility testing determined by Alfred 60\/AST (Alifax\u00ae) in a multi-sites lab: performance's evaluation and optimization of workflow","volume":"194","author":"Cupaiolo","year":"2022","journal-title":"J Microbiol Methods"},{"issue":"3","key":"10.1016\/j.pharma.2022.11.009_bib0305","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1128\/JCM.44.3.1101-1104.2006","article-title":"Accuracy of three automated systems (MicroScan WalkAway, VITEK, and VITEK 2) for susceptibility testing of Pseudomonas aeruginosa against five broad-spectrum beta-lactam agents","volume":"44","author":"Sader","year":"2006","journal-title":"J Clin Microbiol"},{"issue":"11","key":"10.1016\/j.pharma.2022.11.009_bib0310","doi-asserted-by":"crossref","first-page":"e4616","DOI":"10.1093\/cid\/ciaa649","article-title":"Clinical impact of accelerate pheno rapid blood culture detection system in bacteremic patients","volume":"73","author":"Dare","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.pharma.2022.11.009_bib0315","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/cid\/ciab126","article-title":"Implementation of a rapid phenotypic susceptibility platform for gram-negative bloodstream infections with paired antimicrobial stewardship intervention: is the juice worth the squeeze?","volume":"73","author":"Robinson","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.pharma.2022.11.009_bib0320","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1093\/cid\/ciz406","article-title":"Clinical impact of rapid species identification from positive blood cultures with same-day phenotypic antimicrobial susceptibility testing on the management and outcome of bloodstream infections","volume":"70","author":"Ehren","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.pharma.2022.11.009_bib0325","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.cmi.2019.09.023","article-title":"Rapid microbiological tests for bloodstream infections due to multidrug resistant Gram-negative bacteria: therapeutic implications","volume":"26","author":"Giacobbe","year":"2020","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"10.1016\/j.pharma.2022.11.009_bib0330","doi-asserted-by":"crossref","first-page":"e00360","DOI":"10.1128\/JCM.00360-20","article-title":"Impact of rapid antimicrobial susceptibility testing in gram-negative rod bacteremia: a quasi-experimental study","volume":"58","author":"Hogan","year":"2020","journal-title":"J Clin Microbiol"},{"issue":"8","key":"10.1016\/j.pharma.2022.11.009_bib0335","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/j.1469-0691.2009.03044.x","article-title":"Assessment of the usefulness of performing bacterial identification and antimicrobial susceptibility testing 24h a day in a clinical microbiology laboratory","volume":"16","author":"Eveillard","year":"2010","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"10.1016\/j.pharma.2022.11.009_bib0340","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.cmi.2019.04.025","article-title":"How to accelerate antimicrobial susceptibility testing","volume":"25","author":"Idelevich","year":"2019","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10.1016\/j.pharma.2022.11.009_bib0345","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1128\/JCM.01452-16","article-title":"Cost analysis of implementing matrix-assisted laser desorption ionization-time of flight mass spectrometry plus real-time antimicrobial stewardship intervention for bloodstream infections","volume":"55","author":"Patel","year":"2016","journal-title":"J Clin Microbiol"},{"issue":"8","key":"10.1016\/j.pharma.2022.11.009_bib0350","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1128\/JCM.00833-15","article-title":"Cost savings realized by implementation of routine microbiological identification by matrix-assisted laser desorption ionization-time of flight mass spectrometry","volume":"53","author":"Tran","year":"2015","journal-title":"J Clin Microbiol"},{"issue":"10","key":"10.1016\/j.pharma.2022.11.009_bib0355","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1128\/JCM.01405-12","volume":"50","author":"Tan","year":"2012","journal-title":"J Clin Microbiol"},{"issue":"1","key":"10.1016\/j.pharma.2022.11.009_bib0360","first-page":"e01166","article-title":"Use of the accelerate pheno system for identification and antimicrobial susceptibility testing of pathogens in positive blood cultures and impact on time to results and workflow","volume":"56","author":"Charnot-Katsikas","year":"2017","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.pharma.2022.11.009_bib0365","doi-asserted-by":"crossref","first-page":"S177","DOI":"10.1086\/519472","article-title":"Principles of antibiotic therapy in severe infections: optimizing the therapeutic approach by use of laboratory and clinical data","volume":"45 Suppl 3","author":"Deresinski","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pharma.2022.11.009_bib0370","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/jac\/25.suppl_C.81","article-title":"Therapy:the microbiologist's view","volume":"25SupplC","author":"Farrington","year":"1990","journal-title":"J Antimicrob Chemother"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450922001523?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450922001523?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T23:37:02Z","timestamp":1757720222000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450922001523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0003450922001523"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2022.11.009","relation":{},"ISSN":["0003-4509"],"issn-type":[{"type":"print","value":"0003-4509"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Implementing Alfred60AST in a clinical lab: Clinical impact on the management of septic patients and financial analysis","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2022.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}